JY
ANIX icon

Jeff Yass’s Anixa Biosciences ANIX Stock Holding History

Jeff Yass’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$112K Buy
40,100
+5,900
+17% +$16.4K ﹤0.01% 12417
2026
Q1 		$88.2K Buy
34,200
+14,000
+69% +$41.5K ﹤0.01% 12412
2025
Q4 		$63K Buy
+20,200
New +$82.7K ﹤0.01% 11673
2024
Q1 		– Sell
-11,800
Closed -$45.8K – 12098
2023
Q4 		$45.8K Sell
11,800
-26,000
-69% -$87.7K ﹤0.01% 11743
2023
Q3 		$124K Buy
37,800
+11,600
+44% +$40.6K ﹤0.01% 10741
2023
Q2 		$83.8K Buy
+26,200
New +$101K ﹤0.01% 11075
2023
Q1 		– Sell
-18,800
Closed -$79.9K – 12501
2022
Q4 		$79.9K Buy
+18,800
New +$90.4K ﹤0.01% 11126
2022
Q3 		– Sell
-15,400
Closed -$47K – 13102
2022
Q2 		$47K Sell
15,400
-8,700
-36% -$27.4K ﹤0.01% 12007
2022
Q1 		$66K Buy
24,100
+7,800
+48% +$22.9K ﹤0.01% 12160
2021
Q4 		$48K Buy
16,300
+3,200
+24% +$12.9K ﹤0.01% 12564
2021
Q3 		$62K Buy
13,100
+800
+7% +$3.61K ﹤0.01% 12272
2021
Q2 		$48K Buy
+12,300
New +$52.4K ﹤0.01% 12306

Other funds holding ANIX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $5.21B AUM 31.48% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Jeff Yass's ANIX Position: Q2 2026 in Review

Jeff Yass sold out of Anixa Biosciences (ANIX) in Q2 2026, closing a stake of 99,468 shares — an estimated $277K sold.

Jeff Yass first reported a position in ANIX in Q3 2015 and held it in 20 quarters. The position peaked at $1.06M in Q1 2024. 62 funds tracked by Wall St. Rank hold ANIX as of Q2 2026.

  • Jeff Yass reported no remaining Anixa Biosciences position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 99,468 Anixa Biosciences shares in Q2 2026, an estimated $277K.
  • Jeff Yass first reported a position in Anixa Biosciences in Q3 2015 and held it in 20 quarters.
  • Jeff Yass's Anixa Biosciences position peaked at $1.06M in Q1 2024.
  • 62 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.